<!doctype html public "-//w3c//dtd html 4.0 transitional//en">
<html>
Drug companies are interested in canine leishmaniasis instead of human
leishmaniasis for market value of the drugs. Everybody knows it and I talked
about it in WorldLeish II.
<p>KP
<p>Jeffrey J Shaw wrote:
<blockquote TYPE=CITE><x-tab></x-tab>The organizers of the site (<a href="http://www.leishmaniasis.info">www.leishmaniasis.info</a>)
are to be congratulated on its excellent content and quality.
<br> However I would
just like to draw attention to its treatment section which is in my opinion
misleading because it superficially implies that it is successful.
This is corrected in the FAQ number 4<i><font size=-1>"<a NAME="#4"></a>What
treatments can be offered to dogs with CanL<a NAME="#4"></a>? How long
does treatment last? Is it expensive?"</font></i><font size=-1> </font>which
gives a more realistic appraisal of treatment.
<br><x-tab></x-tab>Why try to treat a dog if the "cure rate" is so poor?
What is perhaps more important is that there is potentially a tremendous
danger that this will result in drug resistance. In this respect
there is a great difference between treating a dog in Glasgow than one
in endemic areas such as Minas Gerais or Bahia in Brazil!
<p>Jeffrey Shaw_______________________________________________ leish-l
mailing list leish-l@fat.org.br <A HREF="http://panda.fat.org.br/mailman/listinfo/leish-l">http://panda.fat.org.br/mailman/listinfo/leish-l</A></blockquote>
</html>